We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Tiziana Life Sciences has announced the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for an oral formulation of Foralumab, used for the treatment of autoimmune and inflammatory diseases such as n